Adenium Biotech ApS is developing derivatives of arenicin-3 to create a safer antibiotic than colistin to treat infections caused by multidrug-resistant Gram-negative pathogens.

Colistin is a broad-spectrum Gram-negative antibacterial first introduced in 1952. It was replaced by safer antibacterials in the 1970s due to its nephrotoxicity and neurotoxicity, yet it saw a resurgence in the late 1990s as the last line of defense against multidrug-resistant Gram-negative pathogens.